Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 19/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 16/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5785083 | 0.85 | KDM4E (0.41) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL6095274 | 0.76 | ADORA1 (0.44) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL6094301 | 0.73 | ADORA3 (0.39) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL5742210 | 0.73 | ADORA2B (0.60) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL5741468 | 0.71 | ADORA3 (0.41) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL5741227 | 0.69 | ADORA2B (0.68) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL6095002 | 0.67 | ADORA1 (0.50) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL6094990 | 0.67 | ADORA1 (0.50) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL5741274 | 0.66 | ADORA3 (0.39) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL8705703 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252780-A1 | Fused pyrimidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| EP-1637532-A1 | FUSED PYRIMIDINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252780-A1 | Fused pyrimidine derivatives | INSR, GPR119, NPY4R | ADORA2B 1074/4885ADORA2A 1417/4885ADORA1 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.